Immune checkpoint blockade was already widely used as the most popular anticancer immunotherapy for patients with the advanced driver gene negative NSCLC and could induce tumor cell ferroptosis through the activation of CD8+T cells [62]. Here, CD8A is linked to non-small cell lung carcinoma.